Darshana Dadhania, MD
Nephrology · New York, NYNPI 1861454662
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,325 of the $6,901 with a category attached, or 91.7%. Veloxis Pharmaceuticals, Inc. accounts for 91.7% of it on its own, with 4 other manufacturers making up the rest.
Across 5 payments — averaging $1380.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$6K
- Kaneka Medical America LLC$238
- Sanofi$121
- Vifor Pharma, Inc.$118
- Mallinckrodt Enterprises LLC$100
Across 166 payments — averaging $1261.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$171K
- Travere Therapeutics, Inc.$38K
What the payments were for
- Consulting fees$6,32592%
- Speaking & faculty fees$2383%
- Food & beverage$2383%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 1 | $6,325 |
| Kaneka Medical America LLC | 1 | $238 |
| Sanofi | 1 | $121 |
| Vifor Pharma, Inc. | 1 | $118 |
| Mallinckrodt Enterprises LLC | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$6,325
- LIPOSORBER$238
- THYMOGLOBULIN$121
- Veltassa$118
How this compares
$6,901 in reported general payments places this provider in the 85th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone | 72 | $32,692 |
| JanuviaSitagliptin Phosphate | 37 | $28,728 |
| LokelmaSodium Zirconium Cyclosilicate | 30 | $24,477 |
| AranespDarbepoetin Alfa In Polysorbat | 17 | $19,173 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $11,829 |
| ProcritEpoetin Alfa | 17 | $10,051 |
| EliquisApixaban | 16 | $9,939 |
| Valganciclovir Hcl | 32 | $6,469 |
| Cinacalcet Hcl | 20 | $5,251 |
| Eplerenone | 18 | $2,049 |
| Methenamine Hippurate | 19 | $1,393 |
| Nifedipine ErNifedipine | 42 | $1,377 |
| Repaglinide | 31 | $1,173 |
| Carvedilol | 97 | $814 |
| Fludrocortisone Acetate | 38 | $793 |
Paid to pharmacies, not to this prescriber.
Other nephrology in New York
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
- Jai RadhakrishnanNew York$369K
- Girish NadkarniNew York$281K
- James ChevalierNew York$202K
- David CharytanNew York$164K
- Kirk CampbellNew York$152K
- Andrew BombackNew York$106K
- Alan PerlmanNew York$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.